ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Global molecular epidemiology of carbapenem-resistant Escherichia coli (2002-2017).
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- A systematic review of machine learning on clinical MALDI-TOF MS.Briefings in bioinformatics · 2026Pooled it
- One Health Determinants ofInternational journal of molecular sciences · 2023Pooled it
- Antimicrobial resistance trends of Escherichia coli and Staphylococcus aureus isolated from clinical blood cultures in Namibia: a nine-year (2011-2019) retrospective study.BMC infectious diseases · 2025Article
- Comprehensive Assessment of Initial Adaptation of Extended-Spectrum β-Lactamase-Positive ST131 Escherichia coli to Carbapenem Exposure.The Journal of infectious diseases · 2025Article
- In Silico Detection of Virulence Genes in Whole-Genome Sequences of Extra-Intestinal PathogenicCurrent issues in molecular biology · 2025Article
- Clinical risk factors and outcomes of carbapenem-resistantMicrobiology spectrum · 2024Article
- Detecting Class 1 Integrons and Their Variable Regions inAntibiotics (Basel, Switzerland) · 2024Article
- Characterizing carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Comparison of carbapenem-susceptible and carbapenem-resistantMicrobial genomics · 2023Article
- Carbapenem is not always the best choice in the treatment of septic shock.European journal of medical research · 2023Observational
- Colonization withPathogens (Basel, Switzerland) · 2023Article
- Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones ofLife (Basel, Switzerland) · 2022Review
- Intestinal Persistence of Colonizing Escherichia coli Strains, Especially ST131-H30, in Relation to Bacterial and Host Factors.The Journal of infectious diseases · 2022Article
- Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015-2017.Emerging infectious diseases · 2022Article
- Carbapenemase-Producing Extraintestinal PathogenicFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
The emergence of carbapenem-resistant (CR) Escherichia coli obliges an assessment of such strains' molecular epidemiology. Accordingly, we characterized in detail a globally distributed collection of CR E. coli isolates, then explored for associations between geographical origin and bacterial traits, and between different bacterial traits. We used established PCR-based assays and broth microdilution MIC determinations to characterize 343 global CR (i.e., non-susceptible to ≥ 1 carbapenem) extraintestinal E. coli isolates (2002-2017) for diverse molecular traits-including phylogroups, sequence types (STs), beta-lactamase genes, and 51 virulence genes-and susceptibility to 12 relevant antimicrobial agents. The study population was tremendously diverse according to all assessed variables. Nonetheless, certain geographically aligned, unifying themes emerged. These included an association of an Asia/West Pacific origin with non-B2/D/F phylogroups and STs, lower molecularly inferred virulence, more extensive resistance, and specific resistance genes (notably, metallo-beta-lactamases). Likewise, U.S. isolates from the central region, vs. other regions, were more virulent-appearing and more often from phylogroup B2 and ST131, but less extensively resistant and more often carbapenemase-gene negative. The global CR E. coli population is highly diverse according to multiple characteristics and varies significantly by geographical region. This predictably will pose challenges for prevention and management, and obliges ongoing surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.